Actuate Therapeutics, Inc. Increase (Decrease) in Accounts Payable
Actuate Therapeutics, Inc. (ACTU) reported Increase (Decrease) in Accounts Payable of -$473.40 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-14
- Actuate Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$150.60K, a 129.65% decline year-over-year.
- Actuate Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$322.80K, a 151.88% decline year-over-year.
- Actuate Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $185.56K.
- Actuate Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$1.83M.
- Actuate Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2025 was -$512.54K.
- Actuate Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2024 was -$1.50M, a 216.24% decline from fiscal 2023.
- Actuate Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2023 was $1.29M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$150.60K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$473.40K 10-Q · filed 2026-08-14 | -$287.84K derived: sum of 3 quarters · filed 2026-08-14 | -$2.12M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$322.80K 10-Q · filed 2026-05-14 | -$137.24K derived: sum of 2 quarters · filed 2026-05-14 | -$1.97M derived: sum of 3 quarters · filed 2026-05-14 | -$1.46M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $185.56K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$1.64M derived: sum of 2 quarters · filed 2026-03-26 | -$1.13M derived: sum of 3 quarters · filed 2026-08-14 | -$512.54K 10-K · filed 2026-03-26 |
| 2025-09-30 | -$1.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$1.32M derived: sum of 2 quarters · filed 2026-08-14 | -$698.09K 10-Q · filed 2025-11-13 | -$1.00M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $507.95K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $1.13M 10-Q · filed 2026-08-14 | $827.21K derived: sum of 3 quarters · filed 2026-08-14 | -$2.78M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $622.16K 10-Q · filed 2026-05-14 | $319.26K derived: sum of 2 quarters · filed 2026-05-14 | -$3.29M derived: sum of 3 quarters · filed 2026-05-14 | -$1.36M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$302.90K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$3.91M derived: sum of 2 quarters · filed 2026-03-26 | -$1.98M derived: sum of 3 quarters · filed 2026-03-26 | -$1.50M 10-K · filed 2026-03-26 |
| 2024-09-30 | -$3.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$1.68M derived: sum of 2 quarters · filed 2025-11-13 | -$1.20M 10-Q · filed 2025-11-13 | -$333.06K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $1.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $2.41M 10-Q · filed 2025-08-14 | $3.28M derived: sum of 3 quarters · filed 2025-08-14 | $3.50M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $483.70K 10-Q · filed 2025-05-15 | $1.35M derived: sum of 2 quarters · filed 2025-05-15 | $1.57M derived: sum of 3 quarters · filed 2025-05-15 | |
| 2023-12-31 | $864.68K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $1.08M derived: sum of 2 quarters · filed 2025-03-13 | $1.29M 10-K · filed 2025-03-13 | |
| 2023-09-30 | $219.49K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $426.31K 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | $206.82K 10-Q · filed 2024-09-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B |